Home › NDC Lookup › Ingredients › Silver Sulfadiazine › 43598-0210-50
SSD Cream Silver Sulfadiazine 10 g/1000g Cream, 50 g — NDC 43598-0210-50 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

SSD Cream Silver Sulfadiazine 10 g/1000g Cream, 50 g — NDC 43598-210-50 (Billing 43598-0210-50)

by Dr Reddys Laboratories Inc · 50 g in 1 TUBE

This is a package of 50 g of SSD Cream Silver Sulfadiazine 10 g/1000g Cream from Dr Reddys Laboratories Inc, marketed since May 2011 and currently FDA-listed, this package's marketing is listed to end Dec 2027; retail pharmacies pay about $0.2596 per g (NADAC).

NDC 43598-0210-50
🏷️ FDA NDC (as labeled) 43598-210-50 billing pads the product segment with a zero
This package
Contains50 g Cost per g$0.2596 NADAC Per package$12.98 / 50 g Pack sizes5 compare ↓
Also priced by: Medicaid pays $0.3035/unit · Part D plans $0.2130/unit — full pricing hub ↓
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 43598-210-50 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
43598 labeler · 210 product · 50 package
Package marketed since
May 4, 2011
Package marketing ended
Dec 31, 2027
Sample package
No — commercial package
Billing quantity
50 g per package
Barcode (UPC)
0343598210551, 0343598210858, 0343598210254
Medicaid fills, this package
5,474 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 43598-210-50
Product NDC 43598-210
11-digit billing NDC 43598021050
NCPDP billing unit GM — per gram (weight)
RxCUI 106351, 208185
UNII W46JY43EJR
UPC 0343598210551, 0343598210858, 0343598210254
Application # NDA018578
SPL Set ID 30d6dc33-e457-466b-9159-d8e7cd791820
Established class (EPC) Sulfonamide Antibacterial
Chemical class Sulfonamides
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2011-05-04
Marketing end 2028-01-31
Route TOPICAL
Dosage form CREAM
Substance SILVER SULFADIAZINE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90450030003710
GPI class SSD
GCN Seq No 007669
GCN 31630
HICL code 003347
Ingredient (HICL) Silver Sulfadiazine
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5S
Therapeutic class — specific (HIC3) Topical Sulfonamides
AHFS code 84:04.16.00
AHFS class Astringents, Anti-Infective
FDB label name SSD 1% CREAM
FDB brand name Ssd
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007669
  • GCN: 31630
  • GPI-14 (Medi-Span): 90450030003710
  • HICL (First Databank): 003347
  • AHFS class code: 84:04.16.00
  • RxCUI (RxNorm): 106351
Why two NDCs? The FDA registers this code as 43598-210-50 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 43598-0210-50. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Sulfonamide Antibacterial class.

Pharmacologic class Sulfonamide Antibacterial
Drug family (ATC) Sulfonamides
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name SSD 1% CREAM Ingredient Silver Sulfadiazine
📖 What it is MedlinePlus · NLM

Silver sulfadiazine, a sulfa drug, is used to prevent and treat infections of second- and third-degree burns. It kills a wide variety of bacteria. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It is used along with other burn care to help prevent and treat serious infection in second- and third-degree burns. It is a topical antimicrobial that goes on the skin only.
  • The burn is cleaned first, and then the cream is applied under sterile conditions in a thin layer, usually once or twice a day. Keep the burn covered with cream and reapply if it r...
  • Some people notice burning, rash or skin color changes. Your white blood cell count can also dip temporarily, usually in the first few days. Call your doctor if you notice anything...
  • Get help for widespread rash, blistering or peeling skin, or signs of a serious allergic reaction. Also report unusual bruising or bleeding, frequent infections, or signs of liver...
📖 Read our full Silver Sulfadiazine guide →

Supplement & herbal interactions

Some supplements/herbs that may interact with Silver Sulfadiazine — tap one for details:

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.260 $12.98 / 50 g
Medicaid paysCMS SDUD · 12 mo $0.3035 $15.18 / 50 g
Medicare drug plans payPart D · Q2 2026 $0.2130 $10.65 / 50 g
NADAC price history (per g) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.260 $0.129
▲ Up 98% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
43598-0210-25 43598-210-25 25 g in 1 TUBE $0.3177 / g $7.94 2011-05-04 Sep 30, 2027 Active
43598-0210-40 43598-210-40 400 g in 1 JAR $0.1278 / g $51.12 2011-05-04 Jan 31, 2028 Active
43598-0210-50 You're viewing this 50 g in 1 TUBE $0.2596 / g $12.98 2011-05-04 Dec 31, 2027 Active
43598-0210-55 43598-210-55 Main listing 50 g in 1 JAR $0.2596 / g $12.98 2011-05-04 Nov 30, 2027 Active
43598-0210-85 43598-210-85 85 g in 1 TUBE $0.2609 / g $22.18 2011-05-04 Dec 31, 2027 Active

Per g, this pack runs about 103% above the cheapest pack (400 g, $0.1278 vs $0.2596 NADAC).

This pack accounts for about 22% of this product's recent Medicaid fills; the largest share goes to the 50 g pack. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 50 g — 50 g in 1 tube.
How does this package differ from NDC 43598-0210-25?
Both are SSD Cream Silver Sulfadiazine 10 g/1000g Cream — the drug itself is identical. This page's package is the 50 g one, while NDC 43598-0210-25 is the 25 g package. Per-g NADAC also differs: $0.2596 here vs $0.3177 for the 25 g pack.
What NDC number is used to bill for this package of SSD Cream Silver Sulfadiazine 10 g/1000g Cream?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
SSD Cream 10 g/1000gthis 43598-0210-50 Dr 50 g $0.260 AB Availability likely —
Silver sulfadiazine 10 mg/g 67877-0124-05 Ascend 50 g $0.260 AB Availability likely —
Silver Sulfadiazine 10 mg/g 59762-0131-00 Mylan 1 tube $0.407 AB Availability likely +57%
Silvadene 10 mg/g 61570-0131-20 Pfizer 1 tube $0.433 AB Availability likely +67%
Silvadene 10 mg/g 50090-0230-00 A-S 1 tube — AB FDA listed —
Silver Sulfadiazine 10 mg/g 50090-0607-00 A-S 50 g — AB FDA listed —
Silver Sulfadiazine 10 mg/g 50090-0717-00 A-S 50 g — AB FDA listed —
Silver Sulfadiazine 10 mg/g 50090-0763-00 A-S 25 g — AB FDA listed —
Silver Sulfadiazine 10 mg/g 50090-2152-00 A-S 400 g — AB FDA listed —
Ssd 10 g/1000g 50090-7447-00 A-S 50 g — AB FDA listed —
SSD Cream 10 g/1000g 60760-0962-50 St. 50 g — AB FDA listed —
Silver Sulfadiazine 10 g/1000g 61919-0237-25 DIRECT 25 g — AB FDA listed —
Silver Sulfadiazine 10 mg/g 63187-0023-25 Proficient 25 g — AB FDA listed —
Silver Sulfadiazine 10 mg/g 63629-8768-01 Bryant 20 g — AB Discontinued —
Silver Sulfadiazine 10 mg/g 63629-8769-01 Bryant 25 g — AB Discontinued —
Silver Sulfadiazine 10 mg/g 63629-8770-01 Bryant 50 g — AB Discontinued —
Silver Sulfadiazine 10 mg/g 63629-8771-01 Bryant 50 g — AB Discontinued —
Silver Sulfadiazine 10 mg/g 63629-8772-01 Bryant 85 g — AB Discontinued —
Silver Sulfadiazine 10 mg/g 63629-8773-01 Bryant 400 g — AB Discontinued —
Silver Sulfadiazine 10 g/1000g 68071-2473-05 NuCare 50 g — AB FDA listed —
SSD Cream 10 g/1000g 68071-3867-05 NuCare 50 g — AB FDA listed —
Thermazene Silver Sulfadiazine 10 mg/g 68788-0600-02 Preferred 25 g — AB FDA listed —
SSD Cream 10 g/1000g 68788-8074-02 Preferred 25 g — AB FDA listed —
Silver Sulfadiazine 10 g/1000g 76420-0208-25 Asclemed 25 g — AB FDA listed —
Silver Sulfadiazine 10 mg/g 80425-0221-01 Advanced 50 g — AB FDA listed —
Silver Sulfadiazine 10 mg/g 87063-0078-05 Asclemed 50 g — AB FDA listed —
About this product: this is the brand-name version. We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2011
On the market since
May 2011
📍
2026
Currently FDA-listed
15 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Silver Sulfadiazine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 936JST6JCN
    Cetyl alcohol is a waxy, fatty substance derived from plant or animal sources. It acts as an emulsifier and thickener in medicines, helping blend oil and water components and giving products a smooth, creamy texture.
  • UNII 0RE8K4LNJS
    Isopropyl myristate is an oily liquid made from coconut or palm oil. It's used in medicines as an emollient and penetration enhancer to help the medicine absorb through skin or improve spreadability in topical products.
  • UNII A2I8C7HI9T
    Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
  • UNII 4T6H12BN9U
    Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.
  • UNII 13A4J4NH9I
    A synthetic emulsifier derived from stearic acid and polyethylene glycol. It helps mix oil and water-based ingredients together in liquid medicines and creams to create a smooth, uniform product.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII 06XEA2VD56
    Sorbitan oleate is an emulsifier derived from sorbitol and oleic acid. It helps mix oil and water-based ingredients together and keeps them from separating in the medicine.
  • UNII 2KR89I4H1Y
    Stearyl alcohol is a waxy, fatty substance derived from natural oils or made synthetically. It acts as an emulsifier and thickener in medicines, helping mix ingredients together and give the product the right texture.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

9 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerDr Reddys Laboratories Inc
Application holderDR REDDYS LABORATORIES INC
FDA applicationNDA018578 (NDA)
Labeler code43598
First marketedMay 2011
Product typeHuman Prescription Drug
Portfolio5 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 31 words ▾

INDICATIONS AND USAGE Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns.

⏱️ Dosage and Administration 178 words ▾

DOSAGE AND ADMINISTRATION: FOR TOPICAL USE ONLY - NOT FOR OPHTHALMIC USE: Prompt institution of appropriate regimens for care of the burned patient is of prime importance and includes the control of shock and pain. The burn wounds are then cleansed and debrided; Silver Sulfadiazine Cream is then applied under sterile conditions. The burn areas should be covered with Silver Sulfadiazine Cream at all times.

The cream should be applied once to twice daily to a thickness of approximately one sixteenth of an inch. Whenever necessary, the cream should be reapplied to any areas from which it has been removed due to patient activity. Administration may be accomplished in minimal time because dressings are not required.

However, if individual patient requirements make dressings necessary, they may be used. Reapply immediately after hydrotherapy. Treatment with Silver Sulfadiazine Cream should be continued until satisfactory healing has occurred or until the burn site is ready for grafting.

The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection except if a significant adverse reaction occurs.

⛔ Contraindications 62 words ▾

CONTRAINDICATIONS Silver Sulfadiazine Cream is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation. Because sulfonamide therapy is known to increase the possibility of kernicterus, Silver Sulfadiazine Cream should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.

⚠️ Warnings 76 words ▾

WARNING There is a potential cross-sensitivity between silver sulfadiazine and other sulfonamides. If allergic reactions attributable to treatment with silver sulfadiazine occur, continuation of therapy must be weighed against the potential hazards of the particular allergic reaction. Fungal proliferation in and below the eschar may occur.

However, the incidence of clinically reported fungal superinfection is low. The use of Silver Sulfadiazine Cream in some cases of glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur.

🤒 Adverse Reactions ~1 min read ▾

ADVERSE REACTIONS Several cases of transient leucopenia have been reported in patients receiving silver sulfadiazine therapy. Leucopenia associated with silver sulfadiazine administration is primarily characterized by decreased neutrophil count. Maximal white blood cell depression occurs within two to four days of initiation of therapy.

Rebound to normal leukocyte levels follows onset within two to three days. Recovery is not influenced by continuation of silver sulfadiazine therapy. The incidence of leucopenia in various reports averages about 20%.

A higher incidence has been seen in patients treated concurrently with cimetidine. Other infrequently occurring events include skin necrosis, erythema multiforme, skin discoloration, burning sensation, rashes, and interstitial nephritis. Reduction in bacterial growth after application of topical antibacterial agents has been reported to permit spontaneous healing of deep partial thickness burns by preventing conversion of the partial thickness to full thickness by sepsis.

However, reduction in bacterial colonization has caused delayed separation, in some cases necessitating escharotomy in order to prevent contracture. Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur.

Some of the reactions which have been associated with sulfonamides are as follows: blood dyscrasias, agranulocytosis, aplastic anemia, thrombocytopenia, leucopenia, hemolytic anemia, dermatologic reactions, allergic reactions, Stevens-Johnson syndrome, exfoliative dermatitis, gastrointestinal reactions, hepatitis, hepatocellular necrosis, CNS reactions, and toxic nephrosis.

🧬 Clinical Pharmacology ~1 min read ▾

CLINICAL PHARMACOLOGY Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram-negative and gram-positive bacteria as well as being effective against yeast. Results from in vitro testing are listed below.

Sufficient data have been obtained to demonstrate that silver sulfadiazine will inhibit bacteria that are resistant to other antimicrobial agents and that the compound is superior to sulfadiazine. Studies utilizing radioactive micronized silver sulfadiazine, electron microscopy, and biochemical techniques have revealed that the mechanism of action of silver sulfadiazine on bacteria differs from silver nitrate and sodium sulfadiazine. Silver sulfadiazine acts only on the cell wall to produce its bactericidal effect.

Results of In Vitro Testing With Silver Sulfadiazine Cream, 1% Concentration of Silver Sulfadiazine Number of Sensitive Strains / Total Number of Strains Tested Genus and Species 50 micrograms/mL 100 micrograms/mL Pseudomonas Aeruginosa 130/130 130/130 Xanthomonas (Pseudomonas) Maltophilia 7/7 7/7 Enterobacter Species 48/50 50/50 Enterobacter cloacae 24/24 24/24 Klebsiella Species 53/54 54/54 Escherichia Coli 63/63 63/63 Serratia Species 27/28 28/28 Proteus Mirabilis 53/53 53/53 Morganella Morganii 10/10 10/10 Providencia Rettgeri 2/2 2/2 Proteus Vulgaris 2/2 2/2 Providencia Species 1/1 1/1 Citrobacter Species 10/10 10/10 Acinetobacter Calcoaceticus 10/11 11/11 Stahylococcus Aureus 100/101 101/101 Staphylococcus Epidermidis 51/51 51/51 B-Hemolytic Streptococcus 4/4 4/4 Enterococcus Species 52/53 53/53 Corynebacterium Diphtheriae 2/2 2/2 Clostridium Perfringens 0/2 2/2 Clostridium Perfringens 0/2 2/2 Candida Albicans 43/50 50/50 Silver sulfadiazine is not a carbonic anhydrase inhibitor and may be useful in situations where such agents are contraindicated.

📦 How Supplied / Storage and Handling 92 words ▾

HOW SUPPLIED SSD™ (1% Silver Sulfadiazine) Cream : white to off-white cream. 50 gram jar NDC 43598-210-55 400 gram jar NDC 43598-210-40 25 gram tube NDC 43598-210-25 50 gram tube NDC 43598-210-50 85 gram tube NDC 43598-210-85 SSD AF™ (1% Silver Sulfadiazine) Cream : white to off-white cream. 50 gram jar NDC 43598-211-55 400 gram jar NDC 43598-211-40 Store at controlled room temperature 15° - 30°C (59° - 86°F) SSD is a trademark of Dr.

Reddy's Laboratories, Inc. Manufactured by: Dr. Reddy's Laboratories Louisiana LLC Shreveport, LA 71106 USA Revised, June 2013

📋 Description 113 words ▾

DESCRPITION SSD™ (1% Silver Sulfadiazine Cream) and SSD AF™ (1% Silver Sulfadiazine Cream), 1% are topical antibacterial preparations which have as their active antimicrobial ingredient silver sulfadiazine. The active moiety is contained within an opaque, white, water miscible cream base. Each 1000 grams of SSD/SSD AF Cream contains 10 grams of silver sulfadiazine.

Inactive Ingrediants: cetyl alcohol (SSD Cream only), isopropyl myristate, polyoxyl 40 stearate, propylene glycol, purified water, stearyl alcohol, sodium hydroxide, sorbitan monooleate, white petrolatum; with 0.3% methyl paraben, as a preservative. Silver sulfadiazine has an emprical formula of C 10 H 9 AgN 4 O 2 S, molecular weight of 357.14 and structural formula as shown: Structure for silver sulfadiazine

⚠️ Precautions 133 words ▾

PRECAUTION If hepatic and renal functions become impaired and elimination of the drug decreases accumulation may occur and discontinuation of Silver Sulfadiazine Cream should be weighed against the therapeutic benefit being achieved. In considering the use of topical proteolytic enzymes in conjunction with Silver Sulfadiazine Cream, the possibility should be noted that silver may inactivate such enzymes. Laboratory Tests: In the treatment of burn wounds involving extensive areas of the body, the serum sulfa concentrations may approach adult therapeutic levels (8 to 12mg %).

Therefore, in these patients it would be advisable to monitor serum sulfa concentrations. Renal function should be carefully monitored and the urine should be checked for sulfa crystals. Absorption of the propylene glycol vehicle has been reported to affect serum osmolality, which may affect the interpretation of laboratory tests.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 216 words ▾

Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term dermal toxicity studies of 24 months duration in rats and 18 months in mice with concentrations of silver sulfadiazine three to ten times the concentration in Silver Sulfadiazine Cream revealed no evidence of carcinogenicity. Pregnancy: Pregnancy Category B. A reproductive study has been performed in rabbits at doses up to three to ten times the concentration of silver sulfadiazine in Silver Sulfadiazine Cream and has revealed no evidence of harm to the fetus due to silver sulfadiazine.

There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly justified, especially in pregnant women approaching or at term. (See CONTRAINDICATIONS ) Nursing Mother: It is not known whether Silver Sulfadiazine Cream is excreted in human milk.

However, sulfonamides are known to be excreted in human milk and all sulfonamides derivatives are known to increase the possibility of kernicterus. Because of the potential for serious adverse reactions in nursing infants from sulfonamides, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use: Safety and effectiveness in children have not been established.

(See CONTRAINDICATIONS )

📄 Package Label / Principal Display Panel ~2 min read ▾

Container Label for 25 g Tube SSD™ NDC 43598-210-25 Dr. Reddy’s 25 Grams 1% Silver Sulfadiazine Cream 1% FOR TOPICAL USE ONLY NOT FOR OPHTHALMIC USE Rx Only Silver Sulfadiazine…10mg/g in a hydrophilic base consisting of cetyl alcohol, isopropyl myristate, polyoxyl 40 stearate, propylene glycol, purified water, stearyl alcohol, sodium hydroxide, sorbitan monooleate, white petrolatum; with 0.3% methylparaben, as a preservative. See full prescribing information for dosage and administration.

Store at controlled room 15° - 30°C (59° - 86°F). SSD is a trademark of Dr. Reddy’s Laboratories, Inc.

Manufactured by Dr. Reddy's Laboratories Louisiana, LLC Shreveport, LA 71106 USA Silver Sulfadiazine 1%

Container Label for 50 g Tube SSD™ NDC 43598-210-50 Dr. Reddy’s 50 Grams 1% Silver Sulfadiazine Cream 1% FOR TOPICAL USE ONLY NOT FOR OPHTHALMIC USE Rx Only Silver Sulfadiazine…10mg/g in a hydrophilic base consisting of cetyl alcohol, isopropyl myristate, polyoxyl 40 stearate, propylene glycol, purified water, stearyl alcohol, sodium hydroxide, sorbitan monooleate, white petrolatum; with 0.3% methylparaben, as a preservative. See full prescribing information for dosage and administration.

Store at controlled room 15° - 30°C (59° - 86°F). SSD is a trademark of Dr. Reddy’s Laboratories, Inc.

Manufactured by Dr. Reddy's Laboratories Louisiana, LLC Shreveport, LA 71106 USA Silver Sulfadiazine 1%

Container Label for 85 g Tube SSD™ NDC 43598-210-85 Dr. Reddy’s 85 Grams 1% Silver Sulfadiazine Cream 1% FOR TOPICAL USE ONLY NOT FOR OPHTHALMIC USE Rx Only Silver Sulfadiazine…10mg/g in a hydrophilic base consisting of cetyl alcohol, isopropyl myristate, polyoxyl 40 stearate, propylene glycol, purified water, stearyl alcohol, sodium hydroxide, sorbitan monooleate, white petrolatum; with 0.3% methylparaben, as a preservative. See full prescribing information for dosage and administration.

Store at controlled room 15° - 30°C (59° - 86°F). SSD is a trademark of Dr. Reddy’s Laboratories, Inc.

Manufactured by Dr. Reddy's Laboratories Louisiana LLC Shreveport, LA 71106 USA Silver Sulfadiazine 1%

Container Label for 50 g Jar SSD™ NDC 43598-210-55 Dr. Reddy’s 85 Grams 1% Silver Sulfadiazine Cream 1% FOR TOPICAL USE ONLY NOT FOR OPHTHALMIC USE Rx Only Silver Sulfadiazine…10mg/g in a hydrophilic base consisting of cetyl alcohol, isopropyl myristate, polyoxyl 40 stearate, propylene glycol, purified water, stearyl alcohol, sodium hydroxide, sorbitan monooleate, white petrolatum; with 0.3% methylparaben, as a preservative. See full prescribing information for dosage and administration.

Store at controlled room 15° - 30°C (59° - 86°F). SSD is a trademark of Dr. Reddy’s Laboratories, Inc.

Manufactured by Dr. Reddy's Laboratories Louisiana LLC Shreveport, LA 71106 USA Silver Sulfadiazine 1%

Container Label for 400 g Jar SSD™ NDC 43598-210-40 Dr. Reddy’s 85 Grams 1% Silver Sulfadiazine Cream 1% FOR TOPICAL USE ONLY NOT FOR OPHTHALMIC USE Rx Only Silver Sulfadiazine…10mg/g in a hydrophilic base consisting of cetyl alcohol, isopropyl myristate, polyoxyl 40 stearate, propylene glycol, purified water, stearyl alcohol, sodium hydroxide, sorbitan monooleate, white petrolatum; with 0.3% methylparaben, as a preservative. See full prescribing information for dosage and administration.

Store at controlled room 15° - 30°C (59° - 86°F). SSD is a trademark of Dr. Reddy’s Laboratories, Inc.

Manufactured by Dr. Reddy's Laboratories Louisiana LLC Shreveport, LA 71106 USA Silver Sulfadiazine 1%

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
5.5K
Units reimbursed last 4 qtrs
287.3K
Gross reimbursed last 4 qtrs
$87.2K
Avg / prescription
$15.93
Avg / unit
$0.3035
Latest quarter Q1 2026
613Rx
Medicaid pays / g
$0.3035
gross reimbursed
vs
NADAC / g
$0.2596
acquisition cost
=
Spread
+$0.0439
+17% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
60% FFS 40% MCO
Fee-for-service · 3,283 Rx Managed care · 2,191 Rx
State Medicaid map
Alaska: 1,900 units · 259 per 100k residents AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: 1,600 units · 141 per 100k residents MT North Dakota: no data reported ND Minnesota: 650 units · 11.3 per 100k residents MN Wisconsin: 1,570 units · 26.6 per 100k residents WI Michigan: 15,695 units · 156 per 100k residents MI New York: 102,105 units · 522 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 1,550 units · 36.6 per 100k residents OR Nevada: 2,700 units · 84.5 per 100k residents NV Wyoming: no data reported WY South Dakota: 650 units · 70.7 per 100k residents SD Iowa: 900 units · 28.1 per 100k residents IA Illinois: 3,440 units · 27.4 per 100k residents IL Indiana: 700 units · 10.2 per 100k residents IN Ohio: 4,380 units · 37.2 per 100k residents OH Pennsylvania: 9,330 units · 72.0 per 100k residents PA New Jersey: 21,450 units · 231 per 100k residents NJ Massachusetts: 950 units · 13.6 per 100k residents MA California: 54,442 units · 140 per 100k residents CA Utah: no data reported UT Colorado: 800 units · 13.6 per 100k residents CO Nebraska: 1,050 units · 53.1 per 100k residents NE Missouri: 3,805 units · 61.4 per 100k residents MO Kentucky: 9,436 units · 208 per 100k residents KY West Virginia: 1,500 units · 84.7 per 100k residents WV Virginia: 2,830 units · 32.5 per 100k residents VA Maryland: 1,350 units · 21.8 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: 2,300 units · 31.0 per 100k residents AZ New Mexico: 700 units · 33.1 per 100k residents NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 1,200 units · 16.8 per 100k residents TN North Carolina: 2,400 units · 22.2 per 100k residents NC South Carolina: 1,050 units · 19.5 per 100k residents SC Delaware: no data reported DE Oklahoma: 2,350 units · 58.0 per 100k residents OK Louisiana: 11,327 units · 248 per 100k residents LA Mississippi: 1,050 units · 35.7 per 100k residents MS Alabama: no data reported AL Georgia: 4,650 units · 42.2 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 14,830 units · 48.6 per 100k residents TX Florida: 650 units · 2.9 per 100k residents FL
Units reimbursed · per 100k residents
2.9522
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 522 /100k
2 Alaska 259 /100k
3 Louisiana 248 /100k
4 New Jersey 231 /100k
5 Kentucky 208 /100k
6 Michigan 156 /100k
7 Montana 141 /100k
8 California 140 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
50 g43598-0210-55 9,238 Rx · $140,605
50 g this page43598-0210-50 5,474 Rx · $87,195
400 g43598-0210-40 4,398 Rx · $166,242
25 g43598-0210-25 3,063 Rx · $29,522
85 g43598-0210-85 2,499 Rx · $47,403
Drug total (last 4 qtrs): 24,672 Rx · 2,793,619 units · $470,966 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Silver Sulfadiazine (matched by generic name) — the program that covers self-administered drugs. 2 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Silver Sulfadiazine. CMS lists 3 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$2.77M
Claims incl. refills
136.7K
Beneficiaries
106.4K
Spend / beneficiary
$26.00
Spend / claim
$20.23
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.